Axsome Therapeutics
AXSM
About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Employees: 589
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
70% more repeat investments, than reductions
Existing positions increased: 151 | Existing positions reduced: 89
0.98% more ownership
Funds ownership: 75.87% [Q1] → 76.85% (+0.98%) [Q2]
4% less call options, than puts
Call options by funds: $66.7M | Put options by funds: $69.3M
5% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 57
2% less funds holding
Funds holding: 349 [Q1] → 341 (-8) [Q2]
8% less capital invested
Capital invested by funds: $4.32B [Q1] → $3.95B (-$366M) [Q2]
42% less funds holding in top 10
Funds holding in top 10: 12 [Q1] → 7 (-5) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
|
Wells Fargo
Benjamin Burnett
|
$163
|
Overweight
Assumed
|
3 Sep 2025 |
|
B of A Securities
Jason Gerberry
|
$176
|
Buy
Maintained
|
5 Aug 2025 |
|
RBC Capital
Leonid Timashev
|
$189
|
Outperform
Maintained
|
5 Aug 2025 |
|
Needham
Ami Fadia
|
$150
|
Buy
Reiterated
|
4 Aug 2025 |
|
Morgan Stanley
Sean Laaman
|
$190
|
Overweight
Assumed
|
3 Jul 2025 |
Financial journalist opinion
Based on 5 articles about AXSM published over the past 30 days
